Skip to main content

Table 3 Summary of the eligible studies on MLR in predicting survival, treatment response, and diagnosis in patients with ovarian cancer

From: Independent predictive value of blood inflammatory composite markers in ovarian cancer: recent clinical evidence and perspective focusing on NLR and PLR

Author, Year

Conditions of participants

Significance of marker

Xiang et al. [83], 2017

OCP

Predicting survival: OS

Sastra et al. [57], 2022

EOCP: underwent primary exploratory laparotomy

Predicting treatment response: surgical outcome

Guo et al. [84], 2021

OCP: underwent surgery

Predicting diagnosis: malignant or not, malignant degree

  1. MLR Monocyte-to-lymphocyte ratio, OCP Ovarian cancer patients, EOCP Epithelial ovarian cancer patients, OS Overall survival